Paclitaxel: Clinical Trials

2,873 trials of Paclitaxel, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1401 completed, 359 unknown, 332 recruiting, 317 terminated. 1641 Phase 2, 751 Phase 1, 680 Phase 3, 60 Not applicable, 30 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 21641Completed 771, Unknown 213, Terminated 204, Recruiting 185, Active not recruiting 138, Not yet recruiting 65, Withdrawn 60, Suspended 3, Enrolling by invitation 2
Phase 1751Completed 427, Terminated 103, Recruiting 70, Unknown 57, Active not recruiting 49, Withdrawn 30, Not yet recruiting 9, Suspended 5, Enrolling by invitation 1
Phase 3680Completed 288, Recruiting 110, Unknown 94, Active not recruiting 88, Terminated 61, Not yet recruiting 21, Withdrawn 14, Suspended 4
Not applicable60Completed 21, Recruiting 11, Unknown 11, Not yet recruiting 6, Terminated 4, Active not recruiting 3, Withdrawn 3, Enrolling by invitation 1
Phase 430Completed 12, Unknown 8, Recruiting 4, Terminated 3, Not yet recruiting 2, Withdrawn 1
Early Phase 114Active not recruiting 3, Recruiting 3, Unknown 3, Completed 2, Enrolling by invitation 1, Terminated 1, Withdrawn 1

Follow Paclitaxel: new trials by email Literature Review of Paclitaxel trials Research Report on Paclitaxel

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
HEADWATERS: Gemcitabine vs Paclitaxel in Metastatic Triple-Negative Breast Cancer in Women of African Ancestry.
Gemcitabine (1000 mg/m^2), Paclitaxel 80 mg/m2 weekly - Triple Negative Breast Cancer, Metastatic Triple-negative Breast Cancer
Phase 2Not yet recruitingThe University of The West Indies7502027-06-012026-09-22
Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer
AST-201, Paclitaxel, Carboplatin - Advanced Ovarian Cancer
Phase 2Not yet recruitingAston Sci. Inc.982027-06-012026-10-27
A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck
Cemiplimab, Fianlimab, Carboplatin - Squamous Cell Carcinoma
Phase 2Not yet recruitingUniversity of Chicago902027-02-072026-01-20
Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer
losartan, Paclitaxel - Platinum Resistant Ovarian Cancer
Phase 2Not yet recruitingMassachusetts General Hospital272027-02-012026-09-22
Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung Cancer
Cemiplimab, Pemetrexed (1), Cisplatin - Non-Small Cell Lung Cancer
Phase 2Not yet recruitingMedical University of South Carolina382027-02-012026-11-10
Delayed Application of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer
Cisplatin, Carboplatin, Pemetrexed - Advanced NSCLC, Metastatic NSCLC - Non-Small Cell Lung Cancer
Phase 3Not yet recruitingGoethe University1982027-02-012026-11-17
US/PA/E Imaging for Early Identification of Tumor Response in Patients With Stage II-III Triple Negative Breast Cancer Receiving Neoadjuvant Immunotherapy and Chemotherapy
Elastography, Magnetic Resonance Imaging, Photoacoustic Imaging - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Phase 2Not yet recruitingEmory University322027-01-012026-11-04
Immune Checkpoint Blockade and Chemotherapy With or Without Fecal Microbiota Transplant in Advanced Non-Small Cell Lung Cancer
LND101, Carboplatin, Pemetrexed - Non Small Cell Lung Cancer
Phase 2Not yet recruitingCanadian Cancer Trials Group1602026-12-312026-10-27
Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma
Tislelizumab - Esophageal Cancer
Phase 3Not yet recruitingAsan Medical Center1722026-12-312026-10-29
Aspirin and PAClitaxel in Head & Neck Squamous Cell Carcinoma
Aspirin, Paclitaxel - Head and Neck (HNSCC), Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
Phase 2Not yet recruitingWashington University School of Medicine402026-12-312026-10-28
Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Carboplatin, Paclitaxel, Nab-paclitaxel - Squamous Non-Small Cell Lung Cancer (NSCLC)
Phase 2RecruitingExelixis602026-12-152026-11-12
Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients
Paclitaxel, Carboplatin, Pembrolizumab - Triple Negative Breast Cancer
Phase 1Not yet recruitingWashington University School of Medicine302026-12-012026-11-05
A Study of QLS5132 in Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
QLS5132, Liposomal Doxorubicin, Paclitaxel - Epithelial Ovarian Cancer, Fallopian Tube Cancer
Phase 3Not yet recruitingQilu Pharmaceutical Co., Ltd.4202026-12-012026-11-09
A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)
Pumitamig, Carboplatin, Cisplatin - Early-Stage Non-Small Cell Lung Cancer
Phase 2Not yet recruitingBristol-Myers Squibb802026-11-302026-10-13
Dexamethasone De-Escalation in Neoadjuvant Chemoimmunotherapy for Triple-Negative Breast Cancer
Dexamethasone, Famotidine, Diphenhydramine - Triple Negative Breast Cancer, Triple Negative Breast Cancer (TNBC)
Phase 2Not yet recruitingWashington University School of Medicine172026-11-302026-11-03
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
azacytidine, carboplatin, paclitaxel - Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung
Phase 1 / Phase 2SuspendedNational Cancer Institute (NCI)602026-11-242026-11-19
Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent Endometrial Cancer
Dostarlimab, Carboplatin and paclitaxel - Endometrial Carcinoma, Neoplasms, Endometrial
Phase 3Not yet recruitingGlaxoSmithKline3782026-11-122026-10-19
Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Biospecimen Collection, Computed Tomography, Futibatinib - Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8
Phase 1RecruitingNorthwestern University182026-11-102026-11-19
Lurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small Cell Lung Cancer
Lurbinectedin, Paclitaxel - Carcinoma, Small Cell Lung
Phase 2Not yet recruitingYonsei University692026-11-012026-09-04
Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets
Ivonescimab, Carboplatin, Pemetrexed - Non Small Cell Lung Cancer
Phase 2Not yet recruitingEuropean Organisation for Research and Treatment of Cancer - EORTC1582026-11-012026-06-04

Showing 20 of 2873. Sign in to see all of them.

Conditions studied

Breast Neoplasms (583)  ·  Carcinoma, Non-Small-Cell Lung (503)  ·  Ovarian Neoplasms (335)  ·  Lung Neoplasms (211)  ·  Fallopian Tube Neoplasms (157)  ·  Neoplasms (152)  ·  Stomach Neoplasms (130)  ·  Triple Negative Breast Neoplasms (130)  ·  Esophageal Neoplasms (128)  ·  Neoplasm Metastasis (124)  ·  Carcinoma, Ovarian Epithelial (116)  ·  Endometrial Neoplasms (99)  ·  Squamous Cell Carcinoma of Head and Neck (99)  ·  Uterine Cervical Neoplasms (81)  ·  Esophageal Squamous Cell Carcinoma (80)

Sponsors

National Cancer Institute (NCI) (159)  ·  M.D. Anderson Cancer Center (72)  ·  Merck Sharp & Dohme LLC (72)  ·  Hoffmann-La Roche (64)  ·  AstraZeneca (47)  ·  Bristol-Myers Squibb (45)  ·  Memorial Sloan Kettering Cancer Center (44)  ·  Eli Lilly and Company (38)  ·  Gynecologic Oncology Group (37)  ·  Alliance for Clinical Trials in Oncology (32)  ·  Fudan University (29)  ·  Genentech, Inc. (28)  ·  Novartis Pharmaceuticals (28)  ·  Eastern Cooperative Oncology Group (26)  ·  SWOG Cancer Research Network (26)

Countries

United States (1569)  ·  China (562)  ·  Spain (367)  ·  France (328)  ·  South Korea (323)  ·  Canada (302)  ·  Italy (301)  ·  Germany (292)  ·  United Kingdom (262)  ·  Japan (216)  ·  Belgium (211)  ·  Australia (209)  ·  Taiwan (192)  ·  Poland (189)  ·  Brazil (153)

Top investigators

Norman Wolmark, MD (9)  ·  Corey J. Langer, MD (8)  ·  Francesco Perrone, M.D., Ph.D. (8)  ·  Mariano Provencio, MD (8)

Results publications

PMID 37185961, PMID 34037241, PMID 32450725, PMID 35170751, PMID 38431043, PMID 40966692, PMID 21502559, PMID 21941283, PMID 22646630, PMID 25092775, PMID 30633128, PMID 31395089, PMID 35101941, PMID 37465924, PMID 16236738, PMID 16394300, PMID 18398152, PMID 19692680, PMID 22204724, PMID 22204725, PMID 22508812, PMID 22547591, PMID 23860537, PMID 24077916, PMID 24637997, PMID 24662947, PMID 24794243, PMID 25057165, PMID 25332249, PMID 25366678, PMID 25403584, PMID 26056183, PMID 26101239, PMID 26313683, PMID 26454620, PMID 28196905, PMID 28434660, PMID 29501363, PMID 29562804, PMID 30207593, PMID 30808774, PMID 30976202, PMID 31622131, PMID 32101663, PMID 32305010, PMID 32599071, PMID 33084020, PMID 33154826, PMID 33231285, PMID 33538338

NIH funding

2023 (55), U10CA180868 (53), U10CA027469 (36), 2014 (30), 2016 (29), 2018 (29), U10CA031946 (26), U10CA032102 (25), 2017 (22), 2015 (20), 2025 (19), 2009 (18), 2019 (17), U10CA180820 (16), U10CA021115 (14)